ROLE OF SEX STEROIDS IN AGE-RELATED BONE LOSS
性类固醇在与年龄相关的骨质流失中的作用
基本信息
- 批准号:6200957
- 负责人:
- 金额:$ 24.16万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1999
- 资助国家:美国
- 起止时间:1999-09-01 至 2002-08-31
- 项目状态:已结题
- 来源:
- 关键词:African American adolescence (12-20) aging androgens biomarker blood chemistry bone density bone development bone metabolism caucasian American child physical development estrogens hormone regulation /control mechanism human old age (65+) human subject insulinlike growth factor longitudinal human study middle childhood (6-11) osteocalcin photon absorptiometry physiologic bone resorption racial /ethnic difference sex hormones somatotropin urinalysis
项目摘要
It is believed that peak bone mass is a critical element in the
determination of risk for osteoporotic fractures. At the time of peak bone
there is a 1 SD black-white difference in bone mass which must contribute
greatly to the 50% reduction in osteoporotic fractures among elderly black
men and women in the U.S. This difference in peak bone mass must reflect
processes which differ in black and white children during skeletal growth,
and it is the purpose of Part A of this proposed research to investigate:
l) the black-white differences in rates of gain in bone mass in children
aged 5-14; 2) the relationship between markers of skeletal turnover and
rates of gain in bone mass in black and white children, and whether such
differences account for differences in skeletal growth; and 3) factors
which might influence bone mass either through effects on skeletal
modeling and remodeling during growth, or through other mechanisms,
including sex steroids, growth hormone and other growth factors. In Part
B we propose to also study the role of skeletal remodeling in bone mass
and bone loss differences among black and white adults. We will examine
both differences in bone mass and rates of change in bone mass in older
black and white men and women, and investigate whether changes in rates of
skeletal remodeling are associated with rates of change in skeletal mass.
We will also test whether there are differences in sex steroids which are
associated with differences in bone mass, bone loss, markers of
remodeling, or other potential influences on the skeletal mass (e.g.
muscle mass).
据信,峰值骨量是骨代谢中的关键因素。
确定骨质疏松性骨折风险。在骨峰值的时候
骨量存在1 SD的黑白差异,
大大减少了50%的老年黑人中的骨质疏松性骨折,
美国男性和女性峰值骨量的这种差异必须反映
黑人和白色儿童骨骼生长过程的不同,
本研究建议的A部分的目的是调查:
l)儿童骨量增加率的黑白差异
年龄5-14岁; 2)骨骼转换标志物与
黑人和白色儿童的骨量增加率,
差异解释骨骼生长的差异; 3)因素
这可能会通过影响骨骼,
在生长过程中建模和重塑,或通过其他机制,
包括性类固醇、生长激素和其他生长因子。部分
B我们还建议研究骨骼重建在骨量中的作用
以及黑人和白色成年人之间骨质流失的差异。我们将研究
老年人骨量和骨量变化率的差异
黑人和白色男性和女性,并调查是否变化率,
骨骼重塑与骨骼质量的变化率有关。
我们还将测试性类固醇是否存在差异,
与骨量、骨质流失、
重塑,或对骨骼质量的其他潜在影响(例如,
肌肉质量)。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
C. CONRAD JOHNSTON其他文献
C. CONRAD JOHNSTON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('C. CONRAD JOHNSTON', 18)}}的其他基金
RALOXIFENE HCL AND PLACEBO IN PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSALS
雷洛昔芬盐酸盐和安慰剂预防绝经后骨质疏松症
- 批准号:
6117754 - 财政年份:1998
- 资助金额:
$ 24.16万 - 项目类别:
DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED STUDY ON EFFICACY OF IBANDRONATE
关于伊班膦酸钠疗效的双盲、安慰剂对照、随机研究
- 批准号:
6290933 - 财政年份:1998
- 资助金额:
$ 24.16万 - 项目类别:
RALOXIFENE HCL AND PLACEBO IN PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSALS
雷洛昔芬盐酸盐和安慰剂预防绝经后骨质疏松症
- 批准号:
6291203 - 财政年份:1998
- 资助金额:
$ 24.16万 - 项目类别:
DOUBLE BLIND RANDOMIZED PLACEBO CONTROLLED PARALLEL GROUP MULTICENTER STUDY
双盲随机安慰剂对照平行组多中心研究
- 批准号:
6290990 - 财政年份:1998
- 资助金额:
$ 24.16万 - 项目类别:
RISEDRONATE TO TREAT WOMEN WITH OSTEOPOROSIS RELATED VERTEBRAL DEFORMITIES
利塞膦酸钠治疗患有骨质疏松症相关椎骨畸形的女性
- 批准号:
6291101 - 财政年份:1998
- 资助金额:
$ 24.16万 - 项目类别:
DOUBLE BLIND RANDOMIZED PLACEBO CONTROLLED PARALLEL GROUP MULTICENTER STUDY
双盲随机安慰剂对照平行组多中心研究
- 批准号:
6117745 - 财政年份:1998
- 资助金额:
$ 24.16万 - 项目类别:
IBANDRONATE DURING 3 YEARS TREATMENT FOR OSTEOPOROSIS
伊班膦酸钠治疗骨质疏松症 3 年
- 批准号:
6117775 - 财政年份:1998
- 资助金额:
$ 24.16万 - 项目类别:
RISEDRONATE TO TREAT WOMEN WITH OSTEOPOROSIS RELATED VERTEBRAL DEFORMITIES
利塞膦酸钠治疗患有骨质疏松症相关椎骨畸形的女性
- 批准号:
6290975 - 财政年份:1998
- 资助金额:
$ 24.16万 - 项目类别:
PREVENTION OF BONE LOSS AT THE HIP WITH CALCIUM OR VITAMIN D
使用钙或维生素 D 预防髋部骨质流失
- 批准号:
6290993 - 财政年份:1998
- 资助金额:
$ 24.16万 - 项目类别:
IBANDRONATE DURING 3 YEARS TREATMENT FOR OSTEOPOROSIS
伊班膦酸钠治疗骨质疏松症 3 年
- 批准号:
6290968 - 财政年份:1998
- 资助金额:
$ 24.16万 - 项目类别:














{{item.name}}会员




